Our medicines

We believe in the power of science to tackle some of the most challenging diseases of our time. We have a long history of developing life-saving medicines and a promising pipeline to shape the next generation of treatment options across multiple indications and therapeutic areas.

Report side effects/adverse reactions or product quality complaints

 

Contact us at:

 

Tel: +32 2 352 76 11

E-mail: medicalinfo.belgium@bms.com

 

This list gives an overview of the reimbursed drugs of Bristol Myers Squibb in Belgium in December 2021. 

ABRAXANE (paclitaxel)

AZACTAM (aztreonam)

BARACLUDE (entecavir)

ELIQUIS (apixaban)

EMPLICITI (elotuzumab)

HYDREA (hydroxyurea)

IMNOVID (pomalidomide)

KENACORT-A (triamcinolonacetonide)

OPDIVO (nivolumab)

ORENCIA (abatacept)

REBLOZYL (luspatercept)

REVLIMID (lenalidomide)

REYATAZ (atazanavir sulfate)

SPRYCEL (dasatinib)

VIDAZA (azacitidine)

YERVOY (ipilimumab)

ZEPOSIA (ozanimod)